At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
perampaneldrug
Likely dose
perampanel 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)
In Brief
A Phase 2 clinical trial evaluating perampanel for Refractory Partial Seizures. Completed, enrolled 21 participants across 9 sites.
Detailed Summary
The purpose of this trial is to investigate the safety and tolerability of perampanel in long- term treatment in the patients with refractory partial epilepsy (uncontrolled with other anti-epileptic drugs) who completed Week 10 of Phase II Study E2007-J081-231 study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Partial Seizures
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJun 2009
Primary CompletionAug 2016
Study CompletionOct 2016
TodayJul 2026
First PostedMay 18, 2009
Enrollment StartJun 17, 2009
Primary CompletionAug 8, 2016
Study CompletionOct 31, 2016
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 17.1 years ago
Interventions
perampaneldrug
Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.